Associate VP for Translational Science Wayne State University

Printed as of 4/19/2024

Disclosures

Personal Commercial (23)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------------|--|--------------------------|--|
| Self | . Control of the cont | | 1001071104(0) |
| Alerje | Ownership Interest/Partnership/Principal | None (\$0) | Other |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Beckman Coulter | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| BTG Specialty Pharmacueticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Cardionomics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Emergencies in Medicine | Ownership Interest/Partnership/Principal | Modest (< \$5,000) | Other |
| Heart Beam | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Hemisens | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Life Recovery Systems | Data Safety Monitoring Board | Modest (< \$5,000) | Other |
| Medscape | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Mespere | Ownership Interest/Partnership/Principal | None (\$0) | Heart Failure and Cardiomyopathies |
| Moderna | Consultant Fees/Honoraria | Significant (>= \$5,000) | Other |
| My Patient Insight | Ownership Interest/Partnership/Principal | None (\$0) | General Cardiology Other |
| Pathfast | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| People.Health | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Pfizer Inc | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Quest Diagnostics | Other - Support for COVID-19 community surveillance testing | Significant (>= \$5,000) | Prevention |
| Quidel Ortho | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes General Cardiology Heart Failure and Cardiomyopathies |
| Roche Diagnostics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Siemens | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Tosoh Bioscience, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes Heart Failure and Cardiomyopathies |
| UltraSight Medical | Consultant Fees/Honoraria | Significant (>= \$5,000) | Noninvasive Imaging |
| UltraSight Medical | Ownership Interest/Partnership/Principal | None (\$0) | Noninvasive Imaging |
| | | | |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (7)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|--|--|--------------------------|---------------|
| Self | | | |
| American Heart Association | Research/Research Grants ‡ LEAP-HTN (Linkage, Empowerment, and Access to Prevent Hypertension) | Significant (>= \$5,000) | Prevention |
| Detroit Public Schools Community District | Consultant Fees/Honoraria | Significant (>= \$5,000) | Other |
| Health Partners of Michigan † none | Officer, Director, Trustee, or other Fiduciary Role | None (\$0) | Prevention |
| Michigan Department of Health and Human Services | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| | | | |

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------------|--|--------------------------|------------------------------------|
| Michigan Public Health Institute | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| NIH/NHLBI | Research/Research Grants ‡ DCTP (Detroit Cardiovascular Training Program) | None (\$0) | Heart Failure and Cardiomyopathies |
| NIH/NIMHD | Research/Research Grants ‡ ACHIEVE GREATER (Addressing Cardiometabolic Health Inequities by Early PreVEntion in the Great LakEs Region) | Significant (>= \$5,000) | Other |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (2)

| Funding Source | Institutional Compensation Level |
|--------------------------------|----------------------------------|
| American College of Cardiology | Significant (>= \$5,000) |
| Wayne State University | Significant (>= \$5,000) |

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|------|---|-------------|-------------|--------------------------|
| Self | | | | |
| 2023 | Acute coronary syndromes/coronary heart disease | Plaintiff | | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 1/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 1/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 1/30/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.